{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:08:36Z","timestamp":1793088516979,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research on Digitalization Empowering the Reform of Pathology Teaching"},{"name":"A project of the \"14th Five-Year Plan\" for Educational Science in Liaoning Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-025-00981-y","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:54:04Z","timestamp":1766577244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-parametric MRI radiomics predicts different HER2 expression in breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Siqi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"3","key":"981_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"981_CR2","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1097\/RLU.0000000000003678","volume":"46","author":"N Jokar","year":"2021","unstructured":"Jokar N, Velikyan I, Ahmadzadehfar H, et al. Theranostic approach in breast cancer: A treasured tailor for future oncology. Clin Nucl Med. 2021;46(8):e410\u201320.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"981_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/CCO.0000000000000685","volume":"32","author":"S Pernas","year":"2020","unstructured":"Pernas S, Tolaney SM. Targeting HER2 heterogeneity in early-stage breast cancer. Curr Opin Oncol. 2020;32(6):545\u201354.","journal-title":"Curr Opin Oncol"},{"key":"981_CR4","doi-asserted-by":"crossref","unstructured":"Li Z, Metzger Filho O, Viale G et al. HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. J Clin Invest. 2024;134(7).","DOI":"10.1172\/JCI176454"},{"issue":"8","key":"981_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","volume":"22","author":"Trastuzumab for early-stage","year":"2021","unstructured":"Trastuzumab for early-stage. HER2-positive breast cancer: a meta-analysis of 13\u2008864 women in seven randomised trials. Lancet Oncol. 2021;22(8):1139\u201350.","journal-title":"Lancet Oncol"},{"key":"981_CR6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fonc.2019.01124","volume":"9","author":"A Godoy-Ortiz","year":"2019","unstructured":"Godoy-Ortiz A, Sanchez-Mu\u00f1oz A, Chica Parrado MR, et al. Deciphering HER2 breast cancer disease: biological and clinical implications. Front Oncol. 2019;9:1124.","journal-title":"Front Oncol"},{"issue":"9","key":"981_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol. 2024;21(9):675\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"981_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1574887112666170202165049","volume":"12","author":"R Wuerstlein","year":"2017","unstructured":"Wuerstlein R, Harbeck N. Neoadjuvant therapy for HER2-positive breast cancer. Rev Recent Clin Trials. 2017;12(2):81\u201392.","journal-title":"Rev Recent Clin Trials"},{"issue":"1","key":"981_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"5","key":"981_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11864-023-01068-1","volume":"24","author":"C Corti","year":"2023","unstructured":"Corti C, Giugliano F, Nicol\u00f2 E, et al. HER2-Low breast cancer: a new subtype? Curr Treat Options Oncol. 2023;24(5):468\u201378.","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"981_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","volume":"34","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Viale G, Press MF, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34(8):645\u201359.","journal-title":"Ann Oncol"},{"key":"981_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-1-4939-1050-2_10","volume":"1180","author":"OA Press","year":"2014","unstructured":"Press OA, Guzman R, Cervantes M, et al. Characterization of HER2 status by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Methods Mol Biol. 2014;1180:181\u2013207.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"981_CR13","doi-asserted-by":"publisher","first-page":"100032","DOI":"10.1016\/j.modpat.2022.100032","volume":"36","author":"CJ Robbins","year":"2023","unstructured":"Robbins CJ, Fernandez AI, Han G, et al. Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry. Mod Pathol. 2023;36(1):100032.","journal-title":"Mod Pathol"},{"issue":"9","key":"981_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.5858\/arpa.2023-0187-ED","volume":"147","author":"SJ Schnitt","year":"2023","unstructured":"Schnitt SJ, Tarantino P, Collins LC. The American society of clinical Oncology-College of American pathologists guideline update for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2023;147(9):991\u20132.","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"981_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3348\/kjr.2019.0855","volume":"21","author":"SH Lee","year":"2020","unstructured":"Lee SH, Park H, Ko ES. Radiomics in breast imaging from techniques to clinical applications: A review. Korean J Radiol. 2020;21(7):779\u201392.","journal-title":"Korean J Radiol"},{"issue":"9","key":"981_CR16","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1007\/s00330-024-10641-7","volume":"34","author":"S Zheng","year":"2024","unstructured":"Zheng S, Yang Z, Du G, et al. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics. Eur Radiol. 2024;34(9):6132\u201344.","journal-title":"Eur Radiol"},{"issue":"4","key":"981_CR17","doi-asserted-by":"publisher","first-page":"e2330603","DOI":"10.2214\/AJR.23.30603","volume":"222","author":"Y Peng","year":"2024","unstructured":"Peng Y, Zhang X, Qiu Y, et al. Development and validation of MRI radiomics models to differentiate HER2-Zero, -Low, and -Positive breast cancer. AJR Am J Roentgenol. 2024;222(4):e2330603.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"981_CR18","doi-asserted-by":"publisher","first-page":"e222646","DOI":"10.1148\/radiol.222646","volume":"308","author":"T Ramtohul","year":"2023","unstructured":"Ramtohul T, Djerroudi L, Lissavalid E, et al. Multiparametric MRI and radiomics for the prediction of HER2-Zero, -Low, and -Positive breast cancers. Radiology. 2023;308(2):e222646.","journal-title":"Radiology"},{"issue":"5","key":"981_CR19","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/jmri.28628","volume":"58","author":"X Bian","year":"2023","unstructured":"Bian X, Du S, Yue Z, et al. Potential antihuman epidermal growth factor receptor 2 target therapy beneficiaries: the role of MRI-Based radiomics in distinguishing human epidermal growth factor receptor 2-Low status of breast cancer. J Magn Reson Imaging. 2023;58(5):1603\u201314.","journal-title":"J Magn Reson Imaging"},{"issue":"22","key":"981_CR20","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American pathologists guideline update. J Clin Oncol. 2023;41(22):3867\u201372.","journal-title":"J Clin Oncol"},{"issue":"12","key":"981_CR21","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38(12):1346\u201366.","journal-title":"J Clin Oncol"},{"issue":"9","key":"981_CR22","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206\u201323.","journal-title":"Ann Oncol"},{"issue":"3","key":"981_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.diii.2017.01.001","volume":"98","author":"DA Spak","year":"2017","unstructured":"Spak DA, Plaxco JS, Santiago L, et al. BI-RADS(\u00ae) fifth edition: A summary of changes. Diagn Interv Imaging. 2017;98(3):179\u201390.","journal-title":"Diagn Interv Imaging"},{"issue":"1","key":"981_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-020-05592-8","volume":"181","author":"G Panzironi","year":"2020","unstructured":"Panzironi G, Moffa G, Galati F, et al. Peritumoral edema as a biomarker of the aggressiveness of breast cancer: results of a retrospective study on a 3 T scanner. Breast Cancer Res Treat. 2020;181(1):53\u201360.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"981_CR25","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.4143\/crt.2021.748","volume":"54","author":"HP Kourea","year":"2022","unstructured":"Kourea HP, Dimitrakopoulos FI, Koliou GA, et al. Clinical significance of major Angiogenesis-Related effectors in patients with metastatic breast cancer treated with Trastuzumab-Based regimens. Cancer Res Treat. 2022;54(4):1053\u201364.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"981_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/jmri.26908","volume":"52","author":"M Iima","year":"2020","unstructured":"Iima M, Honda M, Sigmund EE, et al. Diffusion MRI of the breast: current status and future directions. J Magn Reson Imaging. 2020;52(1):70\u201390.","journal-title":"J Magn Reson Imaging"},{"issue":"12","key":"981_CR27","doi-asserted-by":"publisher","first-page":"e2028086","DOI":"10.1001\/jamanetworkopen.2020.28086","volume":"3","author":"Y Yu","year":"2020","unstructured":"Yu Y, Tan Y, Xie C, et al. Development and validation of a preoperative magnetic resonance imaging Radiomics-Based signature to predict axillary lymph node metastasis and Disease-Free survival in patients with Early-Stage breast cancer. JAMA Netw Open. 2020;3(12):e2028086.","journal-title":"JAMA Netw Open"},{"key":"981_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.radonc.2019.04.035","volume":"138","author":"Q Wu","year":"2019","unstructured":"Wu Q, Wang S, Chen X, et al. Radiomics analysis of magnetic resonance imaging improves diagnostic performance of lymph node metastasis in patients with cervical cancer. Radiother Oncol. 2019;138:141\u20138.","journal-title":"Radiother Oncol"},{"issue":"6","key":"981_CR29","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1245\/s10434-019-07300-3","volume":"26","author":"X Zhou","year":"2019","unstructured":"Zhou X, Yi Y, Liu Z, et al. Radiomics-Based pretherapeutic prediction of Non-response to neoadjuvant therapy in locally advanced rectal cancer. Ann Surg Oncol. 2019;26(6):1676\u201384.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"981_CR30","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/jmri.28776","volume":"59","author":"W Jiang","year":"2024","unstructured":"Jiang W, Meng R, Cheng Y, et al. Intra- and peritumoral based radiomics for assessment of lymphovascular invasion in invasive breast cancer. J Magn Reson Imaging. 2024;59(2):613\u201325.","journal-title":"J Magn Reson Imaging"},{"issue":"Suppl 1Suppl 1","key":"981_CR31","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1016\/j.acra.2020.10.015","volume":"29","author":"J Ding","year":"2022","unstructured":"Ding J, Chen S, Serrano Sosa M, et al. Optimizing the peritumoral region size in radiomics analysis for Sentinel lymph node status prediction in breast cancer. Acad Radiol. 2022;29(Suppl 1Suppl 1):S223\u20138.","journal-title":"Acad Radiol"},{"issue":"9","key":"981_CR32","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1007\/s00330-024-10612-y","volume":"34","author":"S Zhao","year":"2024","unstructured":"Zhao S, Li Y, Ning N, et al. Association of peritumoral region features assessed on breast MRI and prognosis of breast cancer: a systematic review and meta-analysis. Eur Radiol. 2024;34(9):6108\u201320.","journal-title":"Eur Radiol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00981-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00981-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00981-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:01:46Z","timestamp":1769515306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-025-00981-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["981"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00981-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6646001\/v1","asserted-by":"object"}]},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of First Affiliated Hospital of Dalian Medical University [IRB number: PJ- KS-KY-2024-69]. Given the retrospective nature of the study, written informed consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}